CN Patent

CN109069426B — 治疗癌症的方法

Assigned to Genzyme Corp · Expires 2021-10-29 · 5y expired

What this patent protects

本发明涉及治疗患有晚期形式的癌症(例如肾透明细胞癌)的患者的方法，其中施用X4P‑001以减少通常伴随TKI疗法发生的血管生成逃逸。这些方法表现出惊人的效果，包括肿瘤大小和细胞数量的退化，且其毒性相对较小。

USPTO Abstract

本发明涉及治疗患有晚期形式的癌症(例如肾透明细胞癌)的患者的方法，其中施用X4P‑001以减少通常伴随TKI疗法发生的血管生成逃逸。这些方法表现出惊人的效果，包括肿瘤大小和细胞数量的退化，且其毒性相对较小。

Drugs covered by this patent

Patent Metadata

Patent number: CN109069426B
Jurisdiction: CN
Classification: —
Expires: 2021-10-29
Drug substance claim: No
Drug product claim: No
Assignee: Genzyme Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.